

1) Status of the notification

Final

2) Issuer

Name TIGENIX
Identification number 0471-340-123

3) Reason for the notification

Conclusion or modification of an agreement to act in concert

4) Notification by

A parent undertaking or a controlling person
Persons acting in concert

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Takeda Pharmaceuticals International AG	Thurgauerstrasse 130, 8152 Glattpark (Opfikon), Switzerland
Takeda Pharmaceutical Company Limited	1-1, Doshomachi 4-Chome, Chuo-ku, Osaka 540-8645, Japan
Gnifols, S.A.	Avenida de la Generalitat 152, 08174 Sant Cugat del Vallès, Barcelona, Spain
Gri-Cel, S.A.	Avenida de la Generalitat 152, 08174 Sant Cugat del Vallès, Barcelona, Spain
Gnifols Worldwide Operations Ltd.	Grange Castle Business Park, Grange Castle, Clondalkin, Dublin 22, Ireland

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

Please continue entering the information in part II concerning the persons referred to in Sections 5 and 6

Part II

7) Date on which the threshold is crossed

05.01.2018 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

15

If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator


274287160

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification # of voting rights	After the transaction			
		# of voting rights		% of voting rights	
		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Takeda Pharmaceuticals International AG	11'651'778	11'651'778	0	4.25%	0.00%
Takeda Pharmaceutical Company Limited	0	0	0	0.00%	0.00%

Subtotal	11'651'778	11'651'778		4.25%	
Gri Cel, S.A	34'188'034	32'238'178	0	11.75%	0.00%
Griols Worldwide Operations Ltd	0	7'189'800	0	2.52%	0.00%
Griols, S.A	0	0	0	0.00%	0.00%
Subtotal	34'188'034	39'427'978		14.37%	
TOTAL		51'079'756	0	18.62%	0.00%

 Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone"
 For groups, start with the ultimate controlling natural person or legal entity.
 The totals, subtotals and % will be updated once you have clicked on <CALCULATE>.

B) Equivalent financial instruments	After the transaction						
	Holder of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL					0	0.00%	

The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
	51'079'768	18.62%

CALCULATE

11. Full chain of controlled undertakings through which the holding is effectively held, if applicable

1. Takeda Pharmaceutical's International AG is controlled by Takeda Pharma A/S, which is controlled by Takeda A/S, which is controlled by Takeda Pharmaceutical Company Limited and by Takeda Europe Holdings B.V., which is controlled by Takeda Pharmaceutical Company Limited. 2. Grifols, S.A. is controlled by Instituto Grifols, S.A., which is controlled by Grifols, S.A. 3. Grifols Worldwide Operations Ltd. is controlled by Grifols, S.A.

12. In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of (DD/MM/YYYY)

13. Additional information

Done at Barcelona, Spain and Osaka, Japan

On 09.01.2018 (DD/MM/YYYY)

Name & capacity Alfredo Arroyo, Chief Financial Officer, Grifols, S.A.
 Misako Hirose, Director, Takeda Pharmaceutical Company Limited

Signature 
 Signature 